- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Biocon Limited — Updates, 07-10-2025: General Updates
07-10-2025 | 08:05 am
07-10-2025 | 08:05 am
Biocon Pharma, a subsidiary, and Carnegie secured tentative US market clearance for Rifaximin Tablets, 550 mg. This drug targets hepatic encephalopathy recurrence and IBS-D, signifying a key business development and potential market entry.
No comments yet. Be the first to comment!